Hard on the heels of its next-gen migraine competitors, Eli Lilly’s Emgality has been looking for a turbo boost. Solid data in preventing migraines as a follow-up treatment could do the trick.
In migraine sufferers who didn't respond to previous prevention regimens, Emgality cut the number of days patients experienced migraines per month by 4.1, a phase 3 trial found. The drug showed a 3.1-day improvement over placebo, Lilly said. Going into the study, the number of migraine days per month was a median 13.4 days.
Emgality also hit key secondary endpoints in the phase 3 study, dubbed Conquer: The drug beat placebo on the percentage of patients who saw their headache days cut by 50%, 75% and 100%, and in improvements in scores on a standard quality-of-life questionnaire, which measures the degree to which migraine limits a person's daily social and work-related activities, Lilly said.
The newest data could help Lilly capitalize on Emgality’s “best-in-class” market access in migraine prevention and cluster headaches, though its sales continue to trail behind those of its fellow CGRP drugs, Amgen’s Aimovig and Teva’s Ajovy.
Last week, Lilly said Emgality held 41% of the new-to-brand market share, a 9% jump from the end of the first quarter. The drugmaker said that capture rate topped the CGRP class, where Emgality was third to market when it launched last year.
RELATED: Lilly's Emgality powers ahead with 'best-in-class' CGRP access
Emgality posted $34 million in sales for the quarter, still far behind those of Aimovig—which hit $83 million in the same period, Amgen reported last week. Teva will present its second-quarter earnings on Wednesday.
While sales continue to lag, Lilly has made a hard pitch to payers for Emgality, and so far it appears to be working: Emgality prescriptions were three-quarters paid for as of last week, and 91.5% of the drug’s migraine patients were covered as of late May.
RELATED: Emgality maker Lilly courts payers with new migraine ER data
In an effort to support that market access, in July, Lilly rolled out a 20,000-patient observational study on preventative migraine treatment, dubbed Overcome, showing that just 5% of frequent migraine sufferers who seek emergency care for their symptoms are treated with a migraine prevention medication like Emgality.
About 15% of the patient pool pursued emergency care within the last 12 months, Lilly said, presenting a clear gap in the number of patients who are eligible for a preventive treatment but aren’t being prescribed one, as well as a need for personalized care outside of the emergency room.
紧随下一代偏头痛竞争者之后，礼来的 Emgality 一直在寻求涡轮增压。可靠的数据在预防偏头痛作为后续治疗可以做到这一点。一项 3 期临床试验发现，在对以前的预防疗法没有反应的偏头痛患者中，Emgality 将患者每月偏头痛发作的天数减少了 4.1 天。礼来表示，与安慰剂相比，该药显示出 3.1 天的改善。进入研究，每月偏头痛发作天数的中位数是 13.4 天。在名为 Conquer 的 3 期研究中，Emgality 也达到了关键的次要终点：在头痛天数减少 50%、75% 和 100% 的患者百分比方面，该药击败了安慰剂，在标准生活质量问卷评分改善方面，该问卷测量了偏头痛限制人日常社交和工作相关活动的程度，Lilly 说。像这样的免费每日通讯？订阅 FiercePharma！生物制药是一个快速增长的世界，每天都有大的想法出现。我们的订户依靠 FiercePharma 作为最新的新闻、分析和数据的必读来源，以及制药公司。今天注册，以获得医药新闻和更新交付到您的收件箱和阅读的走。现在订阅最新的数据可以帮助礼来利用 Emgality 在偏头痛预防和丛集性头痛方面的“同类最佳”市场准入，尽管它的销售额继续落后于它的同类 CGRP 药物，Amgen 的 Aimovig 和 Teva 的 Ajovy。上周，礼来表示，Emgality 占据了最新品牌市场份额的 41%，较一季度末增长了 9%。该制药商表示，捕获率高于 CGRP 类，去年上市时，Emgality 在 CGRP 类市场排名第三。相关：安进上周报告称，礼来的 Emgality powers ahead with'best-in-class'CGRP access Emgality 本季度销售额为 3400 万美元，仍远远落后于 Aimovig——同期销售额高达 8300 万美元。梯瓦将于周三公布第二季度业绩。 While sales continue to lag, Lilly has made a hard pitch to payers for Emgality, and so far it appears to be working: Emgality prescriptions were three-quarters paid for as of last week, and 91.5% of the drug’s migraine patients were covered as of late May. RELATED: Emgality maker Lilly courts payers with new migraine ER data In an effort to support that market access, in July, Lilly rolled out a 20,000-patient observational study on preventative migraine treatment, dubbed Overcome, showing that just 5% of frequent migraine sufferers who seek emergency care for their symptoms are treated with a migraine prevention medication like Emgality. 礼来公司称，在过去 12 个月内，约 15% 的患者接受了紧急治疗，这表明有资格接受预防性治疗但未接受处方治疗的患者数量明显不足，同时急诊室外也需要个性化治疗。
扫码实时看更多精彩文章
微博
微信
提交成功！